Although several studies have assessed the effect of non‐vitamin K antagonist oral
anticoagulants (NOACs) relative to that of vitamin K antagonists (VKAs) in patients with left …

Aims: A meta-analysis was conducted to evaluate the safety and efficacy of novel oral
anticoagulants (NOACs) compared with vitamin K antagonists (VKAs) in patients with left …

Left ventricular thrombus (LVT) is a well-recognized complication of left ventricular systolic
dysfunction, especially in the setting of acute myocardial infarction. It results from the …

Background Although several meta-analyses have compared efficacies of vitamin K
antagonists (VKAs) and direct oral anticoagulants (DOACs) for treatment of left ventricular …

Abstract Background Direct oral anticoagulants (DOACs) have a well-established role in the
treatment of deep vein thrombosis and pulmonary embolism and in the reduction of …

Introduction: Although vitamin K antagonists (VKAs) are recommended as first-line
anticoagulants for patients with left ventricular thrombus (LVT), accumulating evidence …

Introduction: To compare vitamin K antagonists (VKAs) and direct oral anticoagulants
(DOACs) treatment in patients with left ventricular (LV) thrombus. The primary outcome was …

Background: Left ventricular thrombus (LVT) may develop in systolic heart failure or after
acute myocardial infarction. The current recommendations support the use of vitamin K …

Background: Current guidelines recommend vitamin K antagonists (VKAs) for left ventricular
thrombus (LVT) resolution. Direct oral anticoagulants (DOACs) are increasingly evaluated …

Background Current guidelines recommend vitamin K antagonists (VKAs) to reduce the risk
of systemic thromboembolic (STE) events in patients with left ventricular (LV) thrombus …